Clinical characteristics of TFL cohort
. | All TFL patients (n = 155) . | |
---|---|---|
. | (No.) . | (%) . |
Year of FL diagnosis | ||
<2003 | 104 | 67 |
≥2003 | 51 | 33 |
Year of TFL diagnosis | ||
<2003 | 59 | 38 |
≥2003 | 96 | 62 |
Antecedent FL grade | ||
Grade 1 or 2 | 135 | 87 |
Grade 3A | 20 | 13 |
Time to transformation (y) | ||
≤5 | 98 | 63 |
5-10 | 39 | 25 |
>10 | 18 | 12 |
Age at TFL diagnosis (y) | ||
≤60 | 65 | 42 |
>60 | 90 | 58 |
First line treatment of FL | ||
Single-agent chemo | 34 | 24 |
Multi-agent chemo* | 22 | 15 |
Multi-agent chemo† + rituximab | 14 | 10 |
Radiation or surgery | 21 | 15 |
Observation | 52 | 36 |
N/A | 12 | — |
Initial treatment after transformation | ||
Multi-agent chemo‡ | 46 | 32 |
Multi-agent chemo§ + rituximab | 82 | 56 |
Other | 18 | 12 |
N/A | 9 | — |
Hematopoietic stem cell transplant | ||
Autologous | 12 | 8 |
Allogeneic | 3 | 2 |
None | 133 | 90 |
N/A | 7 | — |
Rituximab before transformation | ||
No | 120 | 79 |
Yes | 32 | 21 |
N/A | 3 | — |
Rituximab after transformation | ||
No | 61 | 40 |
Yes | 91 | 60 |
N/A | 3 | — |
. | All TFL patients (n = 155) . | |
---|---|---|
. | (No.) . | (%) . |
Year of FL diagnosis | ||
<2003 | 104 | 67 |
≥2003 | 51 | 33 |
Year of TFL diagnosis | ||
<2003 | 59 | 38 |
≥2003 | 96 | 62 |
Antecedent FL grade | ||
Grade 1 or 2 | 135 | 87 |
Grade 3A | 20 | 13 |
Time to transformation (y) | ||
≤5 | 98 | 63 |
5-10 | 39 | 25 |
>10 | 18 | 12 |
Age at TFL diagnosis (y) | ||
≤60 | 65 | 42 |
>60 | 90 | 58 |
First line treatment of FL | ||
Single-agent chemo | 34 | 24 |
Multi-agent chemo* | 22 | 15 |
Multi-agent chemo† + rituximab | 14 | 10 |
Radiation or surgery | 21 | 15 |
Observation | 52 | 36 |
N/A | 12 | — |
Initial treatment after transformation | ||
Multi-agent chemo‡ | 46 | 32 |
Multi-agent chemo§ + rituximab | 82 | 56 |
Other | 18 | 12 |
N/A | 9 | — |
Hematopoietic stem cell transplant | ||
Autologous | 12 | 8 |
Allogeneic | 3 | 2 |
None | 133 | 90 |
N/A | 7 | — |
Rituximab before transformation | ||
No | 120 | 79 |
Yes | 32 | 21 |
N/A | 3 | — |
Rituximab after transformation | ||
No | 61 | 40 |
Yes | 91 | 60 |
N/A | 3 | — |
Chemo, chemotherapy; N/A, not available.
Ten patients out of 22 were treated with anthracycline-containing regimens.
Three patients out of 14 were treated with cyclophosphamide-doxorubicin-vincristine-prednisone and rituximab (or CHOP-R), and 11 out of 14 with cyclophosphamide-vincristine-prednisone and rituximab.
Forty-one patients out of 46 were treated with anthracycline-containing regimens.
Seventy-seven patients out of 82 were treated with CHOP-R.